Almirall, S.A.

Almirall, S.A. is a global biopharmaceutical company headquartered in Barcelona, Spain, dedicated to medical dermatology. Founded in 1944, its core mission is to transform patients' lives by helping them achieve their hopes and dreams for a healthy life, underpinned by the philosophy to "Feel the Science."

The company focuses on developing and commercializing solutions for dermatological diseases, including psoriasis, actinic keratosis, atopic dermatitis, and acne. Key products in its portfolio include Ilumetri (for psoriasis), Ebglyss (for atopic dermatitis), Wynzora (for psoriasis), Klisyri (for actinic keratosis), and Seysara (for acne). While primarily focused on dermatology, Almirall also has a broader product portfolio that historically covered other therapeutic areas such as the nervous system, gastrointestinal, and cardiovascular systems.

Almirall is publicly traded on the Spanish Stock Exchange (BMAD:ALM) and has established itself as a leading European company in medical dermatology. The company reported strong financial results in 2025, exceeding €1 billion in net sales, driven by its European dermatology business and biologics portfolio, with significant growth from products like Ilumetri and Ebglyss. Carlos Gallardo Piqué serves as the Chairman and CEO. Almirall maintains a global presence, operating in over 100 countries through its affiliates and strategic partnerships, and continues to invest in research and development, including expanding collaborations in areas like AI and High-Performance Computing for dermatological innovation.